You are here: Industry Insights > Bio-Thera

News List

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506 americanpharmaceuticalreview
June 10, 2021
Bio-Thera Solutions Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase III clinical study for BAT2506, a proposed biosimilar of Simponi® (golimumab).
Biogen and Bio-Thera enter licencing agreement for arthritis biosimilar pharmaceutical-technology
April 12, 2021
Biogen and Bio-Thera Solutions have entered an agreement to develop, manufacture and commercialise the anti-interleukin-6 (IL-6) receptor monoclonal antibody BAT1806.
Breaking News! China’s Humira Biosimilar Produced by Bio-Thera to be Marketed Soon PharmaSources/Caicai
November 05, 2019
The marketing application of Bio-Thera’s adalimumab (acceptance No.: CXSS1800018) has recently been under the “under approval” status, which is expected to be approved for marketing soon for treating ankylosing spondylitis (AS).
Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-Enhanced CD20 Monoclonal Antibody americanpharmaceuticalreview
December 10, 2018
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun in a Phase I clinical study of BAT4306F in....